The influence of ANNK1/DRD2 haplotypes on the onset of complications of long-term levodopa therapy in Parkinson’s disease
Objective: To investigate an influence of selected polymorphisms in DRD2 and ANKK1 genes on the occurrence of complications of long-term levodopa therapy in Serbian PD…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate the long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s…Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II
Objective: To evaluate opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations according to disease- and therapy-related characteristics. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: This real-world study evaluated opicapone (OPC) 50-mg in a heterogeneous population of Parkinson’s disease (PD) patients treated in clinical practice. Background: OPC proved effective…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care
Objective: To demonstrate the adverse impact of non-medical switching on patient care. Background: Non-medical switching (NMS) is a policy under which insurers or their pharmacy…Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of baseline OFF-time on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…Therapeutic intervention of LRRK2 kinase inhibitors in Vps35 p.D620N Parkinsonism
Objective: To explore the therapeutic potential of LRRK2 kinase inhibitors in a Vps35 p.D620N mouse model of Parkinsonsim. Background: The discovery of a missense mutation, Vps35 p.D620N…Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) ‘non-responders’ patients who switched from placebo (PLC) or entacapone (ENT) to OPC…Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with or without baseline presence of dyskinesia (BPDys). Background: OPC, a…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 32
- Next Page »